OliX, a RNAi therapeutics developer, gets approval for KOSDAQ listing
- Monday, July 23, 2018, 1:42
- Environment
- Add a comment
SUWON, South Korea, July 23, 2018 /PRNewswire/ — OliX Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, has successfully completed its public listing on the Korea Securities Dealer Automated Quotation (KOSDAQ) in the Korean stock market on July 18. On…
Source: https://www.prnewswire.com:443/news-releases/olix-a-rnai-therapeutics-developer-gets-approval-for-kosdaq-listing-300684665.html
About the Author
adminasapcorp has written 39592 stories on this site.